NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 341 filers reported holding NEKTAR THERAPEUTICS in Q2 2019. The put-call ratio across all filers is 2.70 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $109,000 | -91.6% | 20,156 | -69.1% | 0.00% | -100.0% |
| Q1 2021 | $1,303,000 | -35.7% | 65,154 | -45.3% | 0.01% | -33.3% |
| Q4 2020 | $2,025,000 | +1.2% | 119,149 | -1.2% | 0.01% | +12.5% |
| Q3 2020 | $2,001,000 | -41.5% | 120,603 | -18.4% | 0.01% | -52.9% |
| Q2 2020 | $3,423,000 | +173.0% | 147,814 | +154.4% | 0.02% | +325.0% |
| Q4 2019 | $1,254,000 | -65.4% | 58,097 | -70.8% | 0.00% | -69.2% |
| Q3 2019 | $3,624,000 | -2.4% | 198,960 | +90.6% | 0.01% | 0.0% |
| Q2 2019 | $3,715,000 | +624.2% | 104,406 | +583.8% | 0.01% | +550.0% |
| Q1 2019 | $513,000 | -40.1% | 15,268 | -41.5% | 0.00% | -50.0% |
| Q4 2018 | $857,000 | -93.4% | 26,081 | -87.8% | 0.00% | -91.5% |
| Q3 2018 | $12,997,000 | +948.1% | 213,203 | +739.5% | 0.05% | +840.0% |
| Q2 2018 | $1,240,000 | -63.5% | 25,396 | -20.6% | 0.01% | -68.8% |
| Q1 2018 | $3,400,000 | – | 32,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TIRSCHWELL & LOEWY INC | 588,908 | $7,138,000 | 1.23% |
| Granahan Investment Management | 3,693,956 | $44,771,000 | 1.21% |
| NEA Management Company, LLC | 1,825,600 | $22,126,000 | 1.09% |
| FIC CAPITAL INC | 150,868 | $1,829,000 | 0.75% |
| Rhenman & Partners Asset Management AB | 181,797 | $2,203,000 | 0.66% |
| SOPHROSYNE CAPITAL LLC | 60,200 | $728,000 | 0.64% |
| HARVEY CAPITAL MANAGEMENT INC | 130,400 | $1,580,000 | 0.63% |
| Artal Group S.A. | 1,300,000 | $15,756,000 | 0.57% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 564,418 | $6,840,000 | 0.47% |
| OppenheimerFunds, Inc. | 24,400,000 | $295,728,000 | 0.35% |